Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Melphalan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 4/20 | 0.49 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 0.49 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.46 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Melphalan SCHEMBL5873 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5325132 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL563239 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL414671 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5872 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL41335 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL11029192 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL4150935 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL2680958 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL28782154 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629755-A1 | PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS | Meliatys (FR) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052955-A1 | PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS | MELIATYS (FR) | 2012-04-26 | — | — | WO | claimed |
| US-20240156766-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240139137-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20210379000-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-12-09 | — | — | US | disclosed |
| US-11020363-B2 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10940128-B2 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20210046033-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10864183-B2 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200268698-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-08-27 | — | — | US | disclosed |
| EP-2434886-B1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| CN-106389307-A | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | 锡德克斯药物公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140213650-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| CN-102458114-A | Injectable melphalan compositions containing cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2012-05-16 | — | — | CN | disclosed |
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010138920-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-0728018-B1 | New enzymes and prodrugs for ADEPT | WELLCOME FOUND (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6319702-B1 | NUCLEOTIDE SEQUENCS CODING AN ENZYMATIC POLYPEPTIDE AND CELL TARGETING COMPOUND; FOR USE IN TREATMENT OF CANCER | GLAXO WELLCOME, INC. | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10940128-B2 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | MCL1, MYADM, IL2 | PTGS1 2460/4885CHRM2 4686/4885ADRA2A 3341/4885 |
| US-11020363-B2 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
| US-20200268698-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | PTGS1 2460/4885CHRM2 4686/4885ADRA2A 3341/4885 |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | PTGS1 2460/4885CHRM2 4686/4885ADRA2A 3341/4885 |
| US-20210046033-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
| US-20210379000-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | MCL1, MYADM, IL2 | PTGS1 2460/4885CHRM2 4686/4885ADRA2A 3341/4885 |
| US-20240156766-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | MCL1, MYADM, IL2 | PTGS1 2460/4885CHRM2 4686/4885ADRA2A 3341/4885 |
| US-10864183-B2 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
| US-20140213650-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
| US-20240139137-A1 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | GYS2, NOTUM, PYGL | PTGS1 1980/4885CHRM2 1317/4885ADRA2A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.